In experimental model systems for AF, the inhibition of PARP1 with ABT-888, olaparib or nicotinamide riboside protected against contractile dysfunction by preventing NAD+ depletion and oxidative stress and DNA damage as a result (Table 1). Here, PARP1 is linked to atrial fibrillation.